HRMY250117C45000
- 0.05
- 0.000.00%
Harmony Biosciences Newsroom
The Best U.S. Value Stocks by Quant: AGIO, DLX, PPC
Could The Market Be Wrong About Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Its Attractive Financial Prospects?
H.C. Wainwright Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Maintains Target Price $75
Harmony Biosciences Analyst Ratings
H.C. Wainwright Initiates Harmony Biosciences(HRMY.US) With Buy Rating, Announces Target Price $75
Express News | Harmony Biosciences : H.c. Wainwright Initiates Coverage With Buy Rating; Target Price $75
Piper Sandler Maintains Harmony Biosciences(HRMY.US) With Buy Rating, Raises Target Price to $48
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
There May Be Some Bright Spots In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings
Harmony Biosciences Holdings: Strong Growth Potential and Attractive Valuation Amidst Robust Product Pipeline
Results: Harmony Biosciences Holdings, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Reported Earlier, Harmony Biosciences Shareholders Sell 8M Shares at $31 Each in Public Offering
Harmony Biosciences: JPMorgan Is Sole Manager for Offering >HRMY
Harmony Biosciences Expects Offering to Close Nov. 1 >HRMY
Harmony Biosciences Isn't Offering Any Shares in Offering, Won't Receive Any Proceeds From Sale of Shares >HRMY
Harmony Biosciences: Selling Shareholders Grant Underwriter Option for Additional 1.2M Shares >HRMY
Why Harmony Biosciences (HRMY) Stock Is Down 18% Today
Harmony Biosciences Is Maintained at Overweight by Cantor Fitzgerald
Goldman Sachs Maintains Harmony Biosciences(HRMY.US) With Sell Rating, Maintains Target Price $28